Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT06416007 Not yet recruiting - Cancer Clinical Trials

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

NCT ID: NCT06411015 Completed - Clinical trials for Predictive Cancer Model

Prognostic Evaluation Prediction Model Survival Spinal Epidural Metastases

Start date: January 1, 2021
Phase:
Study type: Observational

Patients with symptomatic spinal metatstasis will be prosepectively included in a database after theu signes informed consent. Minimally six months after inclusion the survival status is analyzed. These are correlated with factors that are used in an earlier develloped prediction model

NCT ID: NCT06410040 Active, not recruiting - Brain Metastases Clinical Trials

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Start date: August 20, 2023
Phase:
Study type: Observational

This study was a retrospective observational study. The study included patients with non-small cell lung cancer with ALK-fusion brain metastases or meningeal metastases who received first-line and late-line treatment with the third-generation ALK TKI lorlatinib between June 2022 and June 2023. Data were collected from the electronic medical records database and hospital information system of many hospitals in Sichuan Province. Clinical pathology features including gender, age, ALK mutation status at diagnosis, and clinical stage at diagnosis were collected from the medical records. The physical condition assessed by ECOG-PS before the administration of lorlatinib was recorded. Information on anti-tumor therapy was obtained from the records, including dose and time of ALK-TKI therapy and tumor response, number of prior systemic therapy lines, drug regimen, efficacy, and whether local therapy such as radiotherapy and surgery had been received. In this study, the sample size is not limited, and information is collected according to the maximum number of patients. The study period was from 01 July 2023 to 30 June 2024.

NCT ID: NCT06408688 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

ISCA-CHECK
Start date: June 2024
Phase: Phase 4
Study type: Interventional

The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to regular cancer treatment with immune checkpoint inhibitors affects: - The immune system's ability to fight cancer - Safety of the treatment - How well the treatment performs against cancer - How the patient feels during treatment Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu with patients treated with imune checkpoint inhibitors only.

NCT ID: NCT06405256 Recruiting - Brain Metastases Clinical Trials

Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases

Start date: January 3, 2020
Phase:
Study type: Observational [Patient Registry]

This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)

NCT ID: NCT06405009 Recruiting - Gastric Cancer Clinical Trials

Prediction Model of Occult Omental Metastasis in Patients With Gastric Cancer

Start date: April 22, 2024
Phase:
Study type: Observational

A complete omentectomy is typically recommended during radical total gastrectomy for gastric cancer, though its impact on survival remains unclear. This study aimed to assess the frequency and risk factors of metastases in the greater omentum in gastric cancer patients undergoing gastrectomy. It will involve a single prospective cohort of consecutive patients who underwent total gastrectomy with complete en bloc omentectomy and modified D2 lymphadenectomy. Post-surgery, the omentum will dissect from the gastrectomy specimen beyond the gastroepiploic vessels and examine separately for pathological assessment. The primary outcome will focus on the detection of omental metastases.

NCT ID: NCT06404593 Completed - Colorectal Cancer Clinical Trials

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Start date: June 18, 2019
Phase:
Study type: Observational

Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.

NCT ID: NCT06401824 Not yet recruiting - NSCLC Stage IV Clinical Trials

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.

NCT ID: NCT06399926 Recruiting - Lung Cancer Clinical Trials

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

Start date: October 30, 2023
Phase:
Study type: Observational

This is a open-label, multi-center prospective observation study for the efficacy and safety of intraventricle pemetrexed disodium via ommaya reservoir in the treatment of leptomeningeal metastasis with lung cancer who have failed at least one targeted therapy. In detail: At least the treatment failure was after third-generation EGFR-TKIs in EGFR-mutated lung cancer; or at least the treatment failure was after second-generation ALK-TKIs in ALK-mutated lung cancer; or at least the treatment failure was after one-line of targeted-TKIs in ROS1-mutated non-squamous non-small lung cancer.

NCT ID: NCT06399159 Completed - Clinical trials for Lymph Node Metastasis

Prediction of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma Based on Ultrasound and Cytological Images

Start date: September 1, 2023
Phase:
Study type: Observational

Rising thyroid carcinoma rates, with papillary thyroid carcinoma (PTC) as the main type (85-90% of cases), often show early cervical lymph node spread. This increases the risk of PTC patients for recurrence and death. A new study's multimodal model fuses preoperative US and cytology images to better predict lymph node metastasis, aiming to improve treatment plans, reduce unnecessary surgeries, and enhance patient outcomes.